Hikma Pharmaceuticals USA Inc.

Hikma Pharmaceuticals USA Inc., doing business as FKA West-Ward Pharmaceuticals, manufactures and supplies generic injectable and non-injectable pharmaceutical products to federal healthcare systems as a prime contractor on full-and-open delivery orders and indefinite delivery vehicles, with no SBA certifications or set-aside designations. The company is a foreign-owned, for-profit manufacturer headquartered in Berkeley Heights, New Jersey, operating under NAICS 325412 (Medicinal and Botanical Manufacturing) and PSC 65 (Drugs and Biologicals).

Hikma's federal footprint is dominated by small-dollar delivery orders for generic injectable medications and tablets supplied to the Defense Logistics Agency (DLA) Troop Support Medical's medical supply chain. Representative recent work includes a $7.521 million definitive contract awarded September 30, 2026, by the Office of the Assistant Secretary for Preparedness and Response for FY26 SNS Pharmaceutical Logistic Replenishment of diazepam (completion September 29, 2027); a $237,342.90 delivery order from DLA Medical Supply Chain on August 25, 2025, for vancomycin 1 gram vials; a $163,152 delivery order on August 25, 2025, for vancomycin supply; multiple $78,537.10 to $1,431.20 delivery orders in July and August 2023 for doxycycline hyclate 100 mg tablets; and sustained naloxone syringe procurements throughout 2023 in the $135 to $951 range. The company supplies critical medications including morphine sulfate, hydromorphone, etomidate, ephedrine sulfate, ketamine, ondansetron, flumazenil, vancomycin, doxycycline, and naloxone to military treatment facilities and Department of Defense operations.

Customer concentration is acute. DLA Troop Support Medical accounts for 412 awards (78.6% of the recent award count) with $56.7 million in combined potential value, while the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 12 anchors the dollar value with 10 awards worth $556.4 million combined potential value—primarily through two major indefinite delivery vehicles. Together, these two customers represent 86% of recent award count and nearly all meaningful dollars. The remaining customer agencies (Office of the Assistant Secretary for Preparedness and Response, National Acquisition Center, and others) contribute scattered lower-value orders.

Hikma holds three major parent vehicles. The largest is Indefinite Delivery Contract SPM2D007D0004, with 234 task orders worth $10.8 million combined potential value, representing the core of DLA Troop Support Medical's recurring small-order pharmaceutical supply chain. A second IDC, SPE2D020D0006, carries 175 task orders worth $2.1 million. Federal Supply Schedule V797P5804X (VA pharmaceuticals and drugs) shows 27 task orders valued at $86.3 million—the second-largest value driver after VISN 12. A single-award Blanket Purchase Agreement for sodium oxybate (XYREM), awarded February 7, 2023, by the National Acquisition Center with a ceiling of $38.5 million, runs through December 17, 2025, and a newly awarded single-award indefinite-delivery contract for hydralazine hydrochloride injections (January 20, 2026, $2.371 million ceiling, four one-year options extending through January 19, 2031) add specialized controlled and restricted-competition vehicle depth. Hikma also sits on the Pharmaceuticals and Drugs GSA Schedule (FSS-61-IB), which has generated three task orders valued at $38.6 million.

Activity has been erratic. The vendor averaged 38 awards in 2022, climbed to 51 in 2023, then dropped sharply to only 7 in 2024 before recovering to 29 in 2025 and 31 in 2026. This volatility reflects the nature of small-order delivery-order procurement against indefinite delivery vehicles rather than steady contract growth. Over the past five years, Hikma has received 524 total awards (100% prime) with a combined potential value of $2 billion, though actual dollars obligated sit at only $25.9 million (1% of the ceiling), consistent with the small per-order pattern. Two awards face recompete within the next twenty-four months with a combined potential value of $7.6 million.

Hikma competes on full-and-open contracts without set-asides, competing directly against other large pharmaceutical manufacturers on commercial-grade generic injectables and controlled substances. The vendor has no subcontract footprint and does not appear as a subcontractor to other federal primes in the source data. Category concentration is pronounced: 411 awards fall under Medicinal and Botanical Manufacturing NAICS, 49 under Pharmaceutical Preparation Manufacturing, with the balance in miscellaneous categories. PSC 65 (Drugs and Biologicals) covers 499 of 524 awards, confirming the narrowly focused pharmaceutical supply mission.